Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP PlatformOctober 19, 2021
Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) PlatformSeptember 28, 2021
Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid SamplesSeptember 28, 2021
Health Tech: Aleksandar Vacic On How Selux Diagnostics’s Technology Can Make An Important Impact In Our Overall WellnessAugust 19, 2021